Results 1 to 10 of about 24,552 (237)

CD39, CD73, and CD38 track tumor burden and reveal immune remodeling during mogamulizumab therapy in Sézary syndrome. [PDF]

open access: yesJ Immunother Cancer
Marchisio S   +13 more
europepmc   +1 more source

Durable immunovirological control after sequential mogamulizumab and tucidinostat in relapsed or refractory adult T-cell leukemia/lymphoma. [PDF]

open access: yesFront Immunol
Jo T   +14 more
europepmc   +1 more source

CCR4-NOT is required for suppressing pervasive transcription and retrotransposable elements. [PDF]

open access: yesJ Biol Chem
Kulkarni SD   +7 more
europepmc   +1 more source

Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy. [PDF]

open access: yesCancers (Basel)
Ni X   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy